Recently, FDA-approved antibody-drug conjugates, Ado-trastuzumab emtansine (Kadcyla®) and trastuzumab deruxtecan (Enhertu®) showed favorable therapeutic efficacy to HER2-positive breast cancer patients as trastuzumab-based drug conjugates. The gene discussed is ERBB2; the disease is breast carcinoma.